Biotech Values

[mcbio]

$SPPI - apaziquone phase 3 fails,SPPI buying ALTH for $1.82/share. Nice redirection, Raj! The master


Adam Feuerstein?@adamfeuersteinReply
$SPPI - apaziquone fails ph 3 bladder cancer trial but Raj is already data-mining, seeking poz spin. And no conf call, naturally

I am curious if SPPI's failure of its bladder cancer drug bodes well for OGXI's bladder cancer drug, in that it's one less competitor in a space that I don't believe is very crowded to begin with, or if it's negative because it shows the difficulty of targeting bladder cancer. I believe the prior results for SPPI's bladder cancer drug were promising. That said, I think OGXI's drug has an entirely different MoA from SPPI's drug, so perhaps this is potentially good news for OGXI.